Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 17;9(1):200.
doi: 10.1038/s41598-018-37570-y.

Real Life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy

Affiliations
Free PMC article

Real Life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy

Lihi Bar-Lev Schleider et al. Sci Rep. .
Free PMC article

Abstract

There has been a dramatic increase in the number of children diagnosed with autism spectrum disorders (ASD) worldwide. Recently anecdotal evidence of possible therapeutic effects of cannabis products has emerged. The aim of this study is to characterize the epidemiology of ASD patients receiving medical cannabis treatment and to describe its safety and efficacy. We analysed the data prospectively collected as part of the treatment program of 188 ASD patients treated with medical cannabis between 2015 and 2017. The treatment in majority of the patients was based on cannabis oil containing 30% CBD and 1.5% THC. Symptoms inventory, patient global assessment and side effects at 6 months were primary outcomes of interest and were assessed by structured questionnaires. After six months of treatment 82.4% of patients (155) were in active treatment and 60.0% (93) have been assessed; 28 patients (30.1%) reported a significant improvement, 50 (53.7%) moderate, 6 (6.4%) slight and 8 (8.6%) had no change in their condition. Twenty-three patients (25.2%) experienced at least one side effect; the most common was restlessness (6.6%). Cannabis in ASD patients appears to be well tolerated, safe and effective option to relieve symptoms associated with ASD.

Conflict of interest statement

L.B.L.S. and N.S. are employees of Tikun-Olam Ltd. V.N. is a paid member of the Tikun Olam Ltd. scientific advisory board. R.M. and G.M. have no conflicts of interest pertaining to the current manuscript.

Figures

Figure 1
Figure 1
The study population in the three follow-up periods, at intake, after one month and after six months of medical cannabis treatment.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Bax M. Autism. Dev Med Child Neurol. 1994;36:659–660. - PubMed
    1. Services, C. D. o. D. (California Health and Human Services Agency, Department of Developmental Services Sacramento, 1999).
    1. Croen LA, Grether JK, Hoogstrate J, Selvin S. The changing prevalence of autism in California. Journal of autism and developmental disorders. 2002;32:207–215. doi: 10.1023/A:1015453830880. - DOI - PubMed
    1. Boyle CA, et al. Trends in the prevalence of developmental disabilities in US children, 1997–2008. Pediatrics. 2011;127:1034–1042. doi: 10.1542/peds.2010-2989. - DOI - PubMed
    1. Lundström S, Reichenberg A, Anckarsäter H, Lichtenstein P, Gillberg C. Autism phenotype versus registered diagnosis in Swedish children: prevalence trends over 10 years in general population samples. bmj. 2015;350:h1961. doi: 10.1136/bmj.h1961. - DOI - PMC - PubMed

Publication types

Substances

Feedback